NCT05500118

Brief Summary

With the younger patients diagnosed with asymptomatic leiomyoma, delay in the reproductive age of women, the advancement of medical technology, and the rapid development of treatment methods, there are many choices between gynecologists, gynecologists and patients because of experience and knowledge. It is not easy to make the most favorable choice for patients. This study is mainly led by a committee composed of designers, doctors, nurses and patients, and based on clinical guidelines and evidence-based medicine. Co-operating with patients with asymptomatic small leiomyoma, we want to find the influencing factors of clinical decision-making, and to establish a patient decision aid tool. We use prospective trial to verify that the use of this tool can improve patients' decision-making efficacy and further improve patient-reported outcomes.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
16mo left

Started Aug 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress74%
Aug 2022Aug 2027

First Submitted

Initial submission to the registry

August 9, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 12, 2022

Completed
19 days until next milestone

Study Start

First participant enrolled

August 31, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2024

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2027

Expected
Last Updated

August 12, 2022

Status Verified

August 1, 2022

Enrollment Period

2 years

First QC Date

August 9, 2022

Last Update Submit

August 10, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Patient satisfaction after using PDAs

    The patients in PDAs will undertake the treatment by PDAs. And we will collect the satisfaction after 12 months.

    6-12 months

Study Arms (2)

communication without PADs

We use traditional communication ways to discuss the conditions with patients.

communication with PADs

The committee, composed of designers, doctors, nurses and patients, bases on guidelines and evidence-based medicine to make a tool. And we use this tool to discuss the conditions with patients.

Other: Patients Decision Aids

Interventions

Patient Decision Aids (PDAs) are an important way to facilitate making decision by patients, helping patients make specific and prudent choices by providing information about treatment options and corresponding outcomes, including benefits and risks, related to their health status. The purpose of PDAs is to encourage patients to participate in decision-making. It makes it easier for patients and doctors to discuss treatment options. It effectively promotes communication between patients and doctors. It can help patients combine their own needs and professional advice to make better, more individualized diagnosis and treatment options.

communication with PADs

Eligibility Criteria

Age18 Years - 55 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

18-55 years old woman diagnosed with uterine fibroids and without clinical symptoms

You may qualify if:

  • Diagnosis of leiomyoma: patients with leiomyoma diagnosed by imaging examinations (ultrasound and MRI) have no clinical symptoms;
  • Female with age in 18-55 years old;
  • The maximum diameter of a single leiomyoma is less than 5m, and the number does not exceed 10 by MRI;
  • No contraindications for sedation and analgesia;
  • Patients and their families agree to join this study, and can follow up on time.

You may not qualify if:

  • History of myomectomy, including transabdominal, laparoscopic, hysteroscopy, etc.;
  • History of connective tissue diseases or radiotherapy, especially abdominal radiotherapy;
  • With pregnancy, acute inflammation of the reproductive tract, or other gynecological benign and malignant diseases such as endometriosis and ovarian tumors;
  • The maximum diameter of leiomyoma is greater than or equal to 5cm;
  • Suspected malignant tumor, such as sarcoma;
  • Those with language communication barriers and unable to cooperate with sedative and analgesic programs;
  • Abdominal scarring, when diagnosed by ultrasound transabdominal scan, has obvious sound attenuation (more than 10mm range).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shenzhen Maternal and Child Health Hospital

Shenzhen, Guangdong, 518000, China

RECRUITING

MeSH Terms

Conditions

Leiomyoma

Condition Hierarchy (Ancestors)

Neoplasms, Muscle TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasms

Central Study Contacts

Yu Dai, Associate Professor

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

August 9, 2022

First Posted

August 12, 2022

Study Start

August 31, 2022

Primary Completion

August 31, 2024

Study Completion (Estimated)

August 31, 2027

Last Updated

August 12, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will not share

Locations